Tizanidine
Product Images NDC 67296-2102

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 67296-2102). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

FDA Label Image

Container2 (Container2)

FDA Label Image

Container3 (Container3)

FDA Label Image

Container4 (Container4)

FDA Label Image

Fig1 (Fig1)

FDA Label Image

Fig2 (Fig2)

This text mentions the improvement in Ashworth Score with 16 mg of tizanidine compared to placebo over time. It likely presents a comparison between the two treatments and their effects in a study, potentially focusing on muscle spasticity or control.*

FDA Label Image

Fig3 (Fig3)

This is a report evaluating the improvement in Ashworth Score with the medication Zanidine at a mean dose of 28.6 mg. The study assesses the Ashworth Score at Study Week 3 and at the End of Maintenance Endpoint, which is at Study Week 7 using the Last Observation Carried Forward method.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.